An association between mutations in EGFR tyrosine kinase sites in NSCLC patients and hyper-responsiveness to gefitinib has recently been reported (Lynch et al, 2004; Paez et al, 2004). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.